Preclinical evidence for neuroprotection with monoamine oxidase-B inhibitors in Parkinson's disease.
about
RanBP2 modulates Cox11 and hexokinase I activities and haploinsufficiency of RanBP2 causes deficits in glucose metabolismThe role of oxidative stress in Parkinson's diseaseMonoaminergic and Histaminergic Strategies and Treatments in Brain DiseasesFunctional models of Parkinson's disease: a valuable tool in the development of novel therapies.Medical management of Parkinson's disease: focus on neuroprotectionPresent and future drug treatment for Parkinson's disease.Thiol-redox signaling, dopaminergic cell death, and Parkinson's diseaseTiming of treatment initiation in Parkinson's disease: a need for reappraisal?A review of pharmacological treatments used in experimental models of traumatic brain injury.Functional mechanism of neuroprotection by inhibitors of type B monoamine oxidase in Parkinson's disease.Monoamine oxidase B inhibitors for the treatment of Parkinson's disease: a review of symptomatic and potential disease-modifying effects.A review: treatment of Alzheimer's disease discovered in repurposed agents.Selegiline reverses aβ₂₅₋₃₅-induced cognitive deficit in male mice.Brain monoamine oxidase B and A in human parkinsonian dopamine deficiency disorders.Quantitation of non-motor symptoms in Parkinson's disease.Parkinson Disease from Mendelian Forms to Genetic Susceptibility: New Molecular Insights into the Neurodegeneration Process.
P2860
Q21145250-02972EEA-11FB-42AD-8153-559F20F84EE8Q24307946-AC046509-F6BF-4945-9F83-B4D803D83AEDQ28066691-43190289-3FAB-4862-BEBB-FCFD13A917EBQ34916732-4F56FB5D-72A0-40CF-B010-7C6C4A6BB0A1Q35092165-0AD07C69-7C6C-4CFA-993B-69E99E39A769Q35484805-4651A2F1-74B1-4CDB-8929-486D342CE7E2Q36326535-B127E128-8A09-442B-B9FD-268D362B6F27Q36401495-532728E8-82B0-418E-8220-5EE8F68CA128Q36799413-61C1E72A-FFAD-48ED-8335-C6BF990B0AAEQ37578490-2920E3F2-0906-4CAE-AF66-6F83885E0A75Q37963572-B17BE9EF-BC23-4261-9DFC-92F98010AB66Q38073138-19A5F391-738C-4A55-8E57-2181125E75ADQ43643813-8D053AAC-F5FF-45CC-B9A8-CB41C69FE65DQ47593688-E55AD650-0C96-4354-982E-87CF34D76750Q48426111-CF9B3B6D-674A-4F7D-BBA4-4535D1A2057FQ52559939-6A0DEA21-79B3-4EBC-80ED-22F46EE0AB45
P2860
Preclinical evidence for neuroprotection with monoamine oxidase-B inhibitors in Parkinson's disease.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Preclinical evidence for neuro ...... bitors in Parkinson's disease.
@ast
Preclinical evidence for neuro ...... bitors in Parkinson's disease.
@en
type
label
Preclinical evidence for neuro ...... bitors in Parkinson's disease.
@ast
Preclinical evidence for neuro ...... bitors in Parkinson's disease.
@en
prefLabel
Preclinical evidence for neuro ...... bitors in Parkinson's disease.
@ast
Preclinical evidence for neuro ...... bitors in Parkinson's disease.
@en
P1433
P1476
Preclinical evidence for neuro ...... bitors in Parkinson's disease.
@en
P2093
Peter Jenner
P304
P356
10.1212/WNL.63.7_SUPPL_2.S13
P407
P433
P577
2004-10-01T00:00:00Z